Navigation Links
Behind the Landmark Weeks Case
Date:1/28/2013

BIRMINGHAM, Ala., Jan. 28, 2013 /PRNewswire/ -- In a landmark decision, the Alabama Supreme Court ruled on January 11, 2013, that a patient who alleges injury from a generic prescription drug can sue makers of the brandname drug for failing to warn about the product's risks.  The ruling, which issued in favor of Plaintiff Danny Weeks, comes after courts across the country have rejected a similar theory of liability.  In his victory, Weeks was represented by attorneys of Heninger Garrison Davis, LLC, who argued the case before the state high court.

"We now have broad daylight for our claims against the brand-makers of Reglan," commented Lew Garrison , the HGD senior partner in charge of the case.  "It is a great win for Danny and vindicates our decision to sue the brand defendants."  The suit is pending in federal court in Montgomery, Alabama, and has been stayed pending the Alabama Supreme Court's decision on the question whether a plaintiff allegedly harmed by a generic medicine can sue the brandmaker of the drug.  The federal court certified the question to the high court.

Danny Weeks alleges that he developed tardive dyskinesia, a movement disorder, from a generic version of the acid reflux drug Reglan, and that the brand-name manufacturers of the medicine (Wyeth LLC, Pfizer Inc., and Schwarz Pharma, Inc.) failed to adequately warn about its risks.  Those brand defendants asked the federal court to certify the question.

In siding with Weeks, the Supreme Court reasoned that "an omission or defect in the labeling for the brand name drug would necessarily be repeated in the generic labeling, foreseeably causing harm to a patient who ingested the generic product."  The court distinguished Weeks' claims and argument from several prior decisions in favor of brand-makers sued by patients who ingest only the generic versions of a drug.  Chris Hood , another of Weeks' attorneys at HGD, called the decision "compelling and well reasoned."

"The Alabama Supreme Court is the first and only supreme court of any state to adopt the theory of liability we advocate," Hood said.  "It correctly identified and applied basic tort principles overlooked by numerous lower courts which rejected similar theories,"  he added.  "The win is tremendously satisfying, particularly because it makes clear that Danny has recourse for his injuries."

Prior to the win, over 70 courts across the country had sided with brand‑makers in similar cases.  Courts in only two states, California and Vermont, have allowed similar claims to proceed. Furthermore, the U.S. Supreme Court decision PLIVA, Inc. v. Mensing, issued in 2011, rejected a plaintiff's suit against generic drug makers for failing to warn about their products' risks.  That decision is based on federal preemption of state tort law.  Commentators agree that it forecloses claims against generic makers for inadequate warnings on drug labels.

"Alabamians injured by generic prescriptions now can hold the brand-maker accountable for understating the risks of the drug," Chris Hood explained.  "It is the right decision, and it stands on settled law of our state."

Alabama for decades has recognized that a person harmed by someone else's misrepresentation can sue that person even if the misrepresentation was made to a third party, not to the person actually harmed by it.  Weeks' claims that the brand-makers of Reglan misinformed his prescribing doctor by understating the risk of contracting tardive dyskinesia from the drug.  The doctor is owed a duty of truth on the part of the brand-makers, Weeks' attorneys argued based on the legal rule known as the learned intermediary doctrine.

Lew Garrison , Weeks' chief attorney, believes the decision may positively influence courts in other states and thereby provide recourse for patients injured by generic replicas of brand drugs. "States which recognize the learned intermediary doctrine and liability for third‑party fraud may follow suit," he predicts.

The following language is required by Rule 7.2 of the Alabama Rules of Professional Conduct:  "No representation is made that the quality of the legal services to be performed is greater than the quality of the legal services performed by other lawyers."

Contact:

Kristi Ozley
kozley@hgdlawfirm.com
Heninger Garrison Davis
2224 1st Avenue North
Birmingham, Alabama 35203
(205) 326‑3336
Toll Free:  1‑800‑241‑9779


'/>"/>
SOURCE Heninger Garrison Davis
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. International Liver Research Community United Behind World Gastroenterology Organisation Action
2. AVAC Report Finds That World is Already Falling Behind Pace to End AIDS Epidemic; Five Essential Actions Needed in 2013 to Avoid Historic Missed Opportunity
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
5. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
6. President Obama Signs Landmark Accessible Prescription Drug Label Bill
7. PRA Participates in Landmark Alzheimers Prevention Clinical Trial
8. SurgiCount Medical Achieves Landmark Product Usage And Customer Milestones
9. Fuse Science Announces Landmark Licensing Agreement with Industry Leader Macular Health
10. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
11. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
Breaking Medicine News(10 mins):